Home › Funds › ARMISTICE CAPITAL, LLC › IMVT

ARMISTICE CAPITAL, LLC position in IMVT

IMMUNOVANT INC COM · Health Care

ARMISTICE CAPITAL, LLC reported holding 1,200,000 shares of IMVT (IMMUNOVANT INC COM) in its Q2 2026 13F filing — a position valued at US$46.2M, representing 0.61% of its reported portfolio and ranking #20 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed IMVT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.20M sh
Reported value held$46.24M
Portfolio Weight0.61%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's IMVT position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in IMVT in Q3 2023 at 1,035,877 shares (US$39.8M). The position peaked in Q3 2025 at 5,836,000 shares, worth US$94.1M. Across 12 filings, ARMISTICE CAPITAL, LLC increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,200,000 shares valued at US$46.2M — a reduction of -700,000 shares quarter over quarter.. Notable position changes include a 133% increase in Q4 2024 (shares fell 31% over the following quarter), a 478% increase in Q2 2025 (shares were roughly flat over the following quarter), a 153% increase in Q1 2026 (shares rose 55% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.04M $39.77M New
Q4 2023 1.44M $60.50M Add
Q1 2024 2.16M $69.92M Add
Q2 2024 3.40M $89.68M Add
Q3 2024 580.00K $16.54M Reduce
Q4 2024 1.35M $33.44M Add
Q1 2025 900.00K $15.38M Reduce
Q2 2025 5.20M $83.20M Add
Q3 2025 5.84M $94.08M Add
Q4 2025 750.00K $19.07M Reduce
Q1 2026 1.90M $47.20M Add
Q2 2026 1.20M $46.24M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IMVT and 13F data

IMVT (IMMUNOVANT INC COM) is a Health Care company. 39 other funds we track also report a position in IMVT — the largest reported positions include Deep Track Capital, LP (US$359.9M), Farallon Capital Management (US$223.7M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$223.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IMVT

All IMVT fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held IMVT?

ARMISTICE CAPITAL, LLC has disclosed IMVT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ARMISTICE CAPITAL, LLC's current position in IMVT?

As of Q2 2026, ARMISTICE CAPITAL, LLC holds 1.20M shares of IMVT (IMMUNOVANT INC COM), valued at $46.24M, representing 0.61% of its reported portfolio and ranking #20.

Has ARMISTICE CAPITAL, LLC been buying or selling IMVT?

In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC reduced its position in IMVT. The position peaked in Q3 2025 at 5.84M shares.

Which other funds hold IMVT?

Other major institutional holders of IMVT include Deep Track Capital, LP, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.